首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 核酸藥物

市場調查報告書

商品編碼

1619081

胜肽治療市場規模、佔有率、成長分析、按類型、按製造商、按合成技術、按給藥途徑、按應用、按地區 - 行業預測，2024-2031

Peptide Therapeutics Market Size, Share, Growth Analysis, By Type (Generic, Innovative), By Type of Manufacturers (In-house, Outsourced), By Synthesis Technology, By Route of Administration, By Application, By Region - Industry Forecast 2024-2031

出版日期: 2024年12月17日 | 出版商:

SkyQuest | 英文 213 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年胜肽治療市場規模估值為406.9億美元，從2023年的431.1億美元成長到2031年的684億美元，預計在預測期（2024-2031年）複合年成長率為5.94%。

由於慢性病盛行率的上升和藥物研發投資的增加，預計對肽療法的需求將顯著成長。隨著患者和醫療保健專業人員越來越認知到這些治療方法的低毒性，市場前景預計將進一步擴大。胜肽合成領域的創新，再加上擴大採用已知能夠精確解決各種疾病狀態的標靶治療，預計將推動銷售。癌症發生率的增加正在推動研究性胜肽療法在腫瘤學中的使用，而政府對生物製藥研究的資助揭示了該領域的新機會。然而，口服生物有效性度有限、製造成本高以及來自生技藥品的競爭等挑戰可能會阻礙長期成長潛力。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 西班牙
- 法國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東/非洲
- 海灣合作理事會國家
- 南非
- 其他中東/非洲

競爭資訊

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2023）
主要企業簡介
- 公司簡介
- 產品系列分析
- 按細分市場分類的佔有率分析
- 收益與前一年同期比較（2021-2023）

主要企業簡介

Eli Lilly and Company
Amgen Inc.
Pfizer Inc.
Bristol-Myers Squibb Company
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited
AstraZeneca PLC
Sanofi SA
GlaxoSmithKline PLC
Novartis AG
Zealand Pharma A/S
AmbioPharm Inc.
Bachem Holding AG
PolyPeptide Group
Circle Pharma, Inc.
PeptiDream Inc.
Apitope Technology Ltd.
Ever Neuro Pharma GmbH
Teva Pharmaceuticals Industries Ltd.
Arch Biopartners Inc.

結論和建議

簡介目錄

Product Code: SQMIG35H2072

Peptide Therapeutics Market size was valued at USD 40.69 billion in 2022 and is poised to grow from USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period (2024-2031).

The demand for peptide therapeutics is poised for significant growth driven by the escalating prevalence of chronic diseases and increased investment in drug discovery. Awareness of the low toxicity associated with these treatments among patients and healthcare professionals is likely to further enhance market prospects. Innovations in peptide synthesis are anticipated to boost sales, complemented by the rising adoption of targeted therapies known for their precision in addressing various medical conditions. The increasing incidence of cancer will catalyze the use of peptide therapeutics in oncology, while supportive government funding for biopharmaceutical research will unveil new opportunities in the sector. However, challenges such as limited oral bioavailability, high production costs, and competition from biologics may hinder long-term growth potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Peptide Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Peptide Therapeutics Market Segmental Analysis

Peptide Therapeutics Market is segmented by Type, Type of Manufacturers, Synthesis Technology, Route of Administration, Application and region. Based on Type, the market is segmented into Generic, Innovative. Based on Type of Manufacturers, the market is segmented into In-house, Outsourced. Based on Synthesis Technology, the market is segmented into Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Technology. Based on Route of Administration, the market is segmented into Parenteral, Oral, Pulmonary, Mucosal, Others. Based on Application, the market is segmented into Metabolic Disorders, Cardiovascular Disorders, Respiratory Disorders, Gastrointestinal Disorders, Infectious Diseases, Pain, Dermatological Disorders, Neurological Disorders, Renal Disorders, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Peptide Therapeutics Market

The peptide therapeutics market is significantly driven by the increasing prevalence of chronic diseases, attributed to unhealthy lifestyle choices and habits that have become more common globally. As conditions such as diabetes and cancer continue to rise, there is an escalating demand for more effective and safer treatment options. Peptide therapeutics are particularly favored due to their low toxicity profiles, making them an appealing alternative for patients suffering from various chronic ailments. This growing recognition of peptide treatments as viable solutions underscores their importance in the evolving landscape of medical therapies, further propelling the market forward.

Restraints in the Peptide Therapeutics Market

The Peptide Therapeutics market faces significant restraints, particularly due to the limited oral bioavailability of peptides. When ingested orally, peptides are prone to degradation by digestive enzymes, which significantly restricts their effective administration in this manner. As a result, most peptide therapeutics are delivered through invasive methods like injections. However, many patients are reluctant to choose these invasive options, as they generally favor non-invasive treatment alternatives. This limitation on administration routes poses a challenge for the growth and acceptance of peptide therapeutics in the market, as it reduces patient adherence and overall treatment satisfaction.

Market Trends of the Peptide Therapeutics Market

The peptide therapeutics market is experiencing a significant trend towards the development of oral formulations, a sector currently underexploited compared to injectables. As consumer preference shifts towards non-invasive administration methods, companies that strategically invest in research to create orally bioavailable peptides stand poised to gain a competitive edge. The challenges of oral delivery, such as stability and absorption, are substantial, but the potential rewards are immense, including increased patient compliance and expanded market share. Investments in innovative drug delivery technologies and formulations could yield transformative products, propelling industry growth and establishing new standards in peptide therapeutics by 2025 and beyond.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Driver & Opportunities
- Restraints & Challenges
Porters Analysis & Impact
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2023
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technological Advancement
Regulatory Landscape
Case Studies
Customer & Buying Criteria Analysis

Global Peptide Therapeutics Market Size by Type & CAGR (2024-2031)

Market Overview
Generic
Innovative

Global Peptide Therapeutics Market Size by Type of Manufacturers & CAGR (2024-2031)

Market Overview
In-house
Outsourced

Global Peptide Therapeutics Market Size by Synthesis Technology & CAGR (2024-2031)

Market Overview
Solid Phase Peptide Synthesis (SPPS)
Liquid Phase Peptide Synthesis (LPPS)
Hybrid Technology

Global Peptide Therapeutics Market Size by Route of Administration & CAGR (2024-2031)

Market Overview
Parenteral Route
Oral Route
Pulmonary
Mucosal
Others

Global Peptide Therapeutics Market Size by Application & CAGR (2024-2031)

Market Overview
Cancer
Metabolic Disorders
Cardiovascular Disorders
Respiratory Disorders
Gastrointestinal Disorders
Infectious Diseases
Pain
Dermatological Disorders
Neurological Disorders
Renal Disorders
Others

Global Peptide Therapeutics Market Size & CAGR (2024-2031)

North America, (Type, Type of Manufacturers, Synthesis Technology, Route of Administration, Application)
- US
- Canada
Europe, (Type, Type of Manufacturers, Synthesis Technology, Route of Administration, Application)
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific, (Type, Type of Manufacturers, Synthesis Technology, Route of Administration, Application)
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
Latin America, (Type, Type of Manufacturers, Synthesis Technology, Route of Administration, Application)
- Brazil
- Rest of Latin America
Middle East & Africa, (Type, Type of Manufacturers, Synthesis Technology, Route of Administration, Application)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2023
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zealand Pharma A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AmbioPharm Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bachem Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PolyPeptide Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Circle Pharma, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PeptiDream Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apitope Technology Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ever Neuro Pharma GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceuticals Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Arch Biopartners Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments